Related Experiment Videos
Optimizing healthcare resources in pyogenic liver abscess: a dual-threshold HDL-CRP model for predicting
Mingzhu Tao1,2,3,4,5,6,7, Muye Xia1,2,3,4,5,6,7, Suling Chen1,2,3,4,5,6,7
1Department of Infectious Diseases, Nanfang Hospital, Southern Medical University, Guangzhou, China.
Background:
Prolonged hospitalization for pyogenic liver abscess (PLA) burdens patients and health systems. We examined whether admission high-density lipoprotein cholesterol (HDL-C) predicts length of stay (LOS) and whether a simple HDL-C-reactive protein (CRP) dual-threshold can flag patients at risk of prolonged stay.
Methods:
We analyzed a prospective adult PLA cohort at a tertiary center (2018-2023; n = 138) and validated findings in MIMIC-IV ICU patients with liver abscess (n = 38) and in NHANES 2017-2020 (n = 9,226). Multivariable models related admission HDL-C to log-transformed LOS; model performance and calibration were assessed with internal resampling and external validation. We further evaluated a dual-threshold rule and conducted mediation analysis with CRP.
Results:
Lower HDL-C independently associated with longer LOS. A nomogram combining HDL-C, abscess size, and sepsis performed well (R 2≈0.66; RMSE≈6.4 d) and remained directionally consistent across external datasets. A dual-threshold (HDL-C < 1.03 mmol/L and CRP > 1.0 mg/dL) identified a high-risk subgroup with greater odds of prolonged stay. CRP mediated a small proportion of the HDL-C-LOS association.
Conclusion:
Admission HDL-C, particularly when interpreted together with CRP, may help identify PLA patients at increased risk of prolonged hospitalization at the time of admission. Patients with low HDL-C and high CRP may warrant closer monitoring, earlier evaluation for source control or drainage, and more proactive inpatient planning. Prospective implementation studies are warranted.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
A recent model describes pravastatin's hepatobiliary excretion, mediated...
Acute Pyelonephritis II: Diagnostic Studies and Management